Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Blood (2025) 146 (Supplement 1): 766.

https://doi.org/10.1182/blood-2025-766

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

The association of a novel psychosocial and mobility assessment with outcomes of veterans with acute myeloid leukemia (AML)

Michelle Lee, Nhan Do, Mary Brophy, Amir Fathi, Areej El-Jawahri, Gabriela Hobbs, Elyse Park, Nathanael Fillmore, Clark DuMontier, Jennifer La

Blood (2025) 146 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2025-2836

Published: 2025

Journal Articles

Adjudicated clinical outcomes of plasma microbial cell-free DNA surveillance in neutropenic patients with Acute Myeloid Leukemia undergoing outpatient chemotherapy

Michael Mansour, Amir Fathi, Andrew Brunner, Musie Ghebremichael, Hailey Warren, Elizabeth Trull, Maria Lampou

Blood (2025) 146 (Supplement 1): 5189.

https://doi.org/10.1182/blood-2025-5189

Published: 2025

Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Blood (2025) 146 (Supplement 1): 992.

https://doi.org/10.1182/blood-2025-992

Published: 2025

Journal Articles

Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes

Katherine Feder, Jessica Freydman, Yue Ren, Shruti Gajjar, Victor You, David Sirignano, Svitlana Tyekucheva, Andrew Brunner, Jean M. Connors, Daniel Deangelo, Amir Fathi, Jacqueline Garcia, Chi-Joan How, Marlise Luskin, Richard Stone, Virginia Volpe, Michelle Lee, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 7338.

https://doi.org/10.1182/blood-2025-7338

Published: 2025

Journal Articles

A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS

Aleksandra Filipovic, Amir Fathi, Noah Merin, Keri Maher, Rabin Niroula, Dale Schaar, Guenther Koehne, Joseph Maly, Jay Yang, Deepa Jeyakumar

Blood (2025) 146 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2025-1648

Published: 2025

Journal Articles

A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies

Brandon Aubrey, Peter Miller, Timothy Graubert, Yi-Bin Chen, Rohiverth Guarecuco, Amir Fathi, Robert Hasserjian, Andrew Brunner

Blood (2025) 146 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2025-2086

Published: 2025

Journal Articles

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 6.

https://doi.org/10.1182/blood-2025-6

Published: 2025

Journal Articles

Real-world outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia treated with IDH1 and IDH2 inhibitors in the frontline setting

Alifya Lokhandwala, Cilomar Martins de Oliveira Filho, Philip Amrein, Amir Fathi, Gabriela Hobbs, Hanno Hock, Rupa Narayan, Andrew Brunner, Michelle Lee

Blood (2025) 146 (Supplement 1): 8171.

https://doi.org/10.1182/blood-2025-8171

Published: 2025

Journal Articles

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Jenny O'Nions, Andrew Wei, Jordi Esteve, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Hartmut Döhner, Amber D'Souza, James Dugan, Amir Fathi, Pasquale Fedele, Lucille Ferrante, Rachel Kobos, Ana Garrido, Sara Garrido Paniagua, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Danielle Trancucci, Naa Sackey, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Christian Recher, Christoph Röllig, Olga Salamero, Prathap Nagaraja Shastri, Tim Sauer, Dr. Emma Searle, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Uwe Platzbecker, Sylvain Garciaz

Blood (2025) 146 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2025-5200

Published: 2025

Journal Articles

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Hartmut Döhner, Andre Schuh, Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Amber D'Souza, James Dugan, Jordi Esteve, Amir Fathi, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Olga Salamero, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sara Garrido Paniagua, Naa Sackey, Tim Sauer, Dr. Emma Searle, Prathap Nagaraja Shastri, Danielle Trancucci, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Andrew Wei, Christoph Röllig

Blood (2025) 146 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2025-5199

Published: 2025

Journal Articles

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

Sangeetha Venugopal, Neil Palmisiano, Guru Subramanian Guru Murthy, Theodore Braun, Alex Ambinder, Jonathan Feld, Sharad Khurana, Stephen Strickland, Rajneesh Nath, Konstantinos Sdrimas, Raquel Ruiz, Beatriz Bruno, Sonia Gutierrez, Douglas Faller, Ana Limon, Amir Fathi

Blood (2025) 146 (Supplement 1): 5197.

https://doi.org/10.1182/blood-2025-5197

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

The association of a novel psychosocial and mobility assessment with outcomes of veterans with acute myeloid leukemia (AML)

Adjudicated clinical outcomes of plasma microbial cell-free DNA surveillance in neutropenic patients with Acute Myeloid Leukemia undergoing outpatient chemotherapy

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes

A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS

A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Real-world outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia treated with IDH1 and IDH2 inhibitors in the frontline setting

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only